The European Commission has given approval to saxaglipti, to be marketed under the brand name Onglyza, for use as a combination therapy by adult patients with type 2 diabetes to help improve their control of blood sugar levels.
Onglyza, which has been developed by pharma giants Bristol-Myers Squibb and AstraZenecan, was approved from Phase 3b 24-week data that showed Onglyza 5 mg added to insulin, with or without metformin, could substantially lower blood sugar levels as compared with a placebo added to insulin, with or without metformin.
It was also found that during the 28-week extension period of the study, Onglyza 5 mg added to insulin, with or without metformin, maintained a lowering of HbA1c levels from 24 to 52 weeks as compared with a placebo.
Onglyza is to be used in combination with drugs such as metformin, thiazolidinedione, sulphonylurea or insulin, if each of these is insufficient on their own to offer sufficient glycaemic control to patients. The approval of Onglyza in Europe provides another option for treating type 2 diabetes, particularly as a large number of patients will eventually have to use insulin to treat their condition.
However, it is advised that Onglyza should not be taken by people with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis, and should not be seen just as an alternative to insulin.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Public Health England considers low carb approach for type 2 diabetes

The low carb approach is being considered by the government to be…

Type 2 diabetes found to be a ‘significant risk factor’ among stroke victims

More evidence has been published which supports that diabetes is a “significant…

Conversation about doctors’ appointments occurring virtually rumbles on

More than half of GP appointments are still being delivered remotely in…